Please go to the PowerPak homepage
and select a course.
The Fundamental Role of the Pharmacist in the Comprehensive Management of Patients With COPD
June 10, 2016
Expiration Date: June 9, 2017
Time to Complete Activity: 30 minutes
Activity Description and Educational Objectives
In this activity, experts in chronic obstructive pulmonary disease (COPD) discuss available as well as emerging treatments and delivery devices for COPD and explore the pharmacists' role in the comprehensive management of patients with this disease.
Upon completion of this activity, participants will be able to:
- Evaluate currently available as well as emerging agents used to treat COPD in terms of their mechanism of action, efficacy, and safety
- Describe available and emerging delivery devices for COPD treatments as well as factors that influence the selection of a particular drug delivery system
- Apply strategies to effectively communicate with COPD patients regarding their disease, avoidance of risk factors, treatment goals, proper inhaler technique, pulmonary rehabilitation, and the importance of medication adherence
- Employ approaches to monitor patients with COPD for treatment response, immunization status, success in smoking cessation, proper inhaler use, and medication adherence
This activity has been designed to meet the educational needs of pharmacists and other clinicians involved in the care of patients with COPD.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: June 10, 2016 - June 10, 2017
Time to Complete: 30 minutes
Faculty & Disclosure/Conflict of Interest Policy
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CPE activity for any amount during the past 12 months.
David M. Mannino, MD
Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
University of Kentucky Medical Center, College of Public Health
David M. Mannino, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Sunovion Pharmaceuticals Inc.
Advisory Board for Amgen Inc.; Boehringer Ingelheim GmbH; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; and Sunovion Pharmaceuticals Inc.
David M. Mannino, MD does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Treatments used off-label in COPD, as well as drugs being investigated for this disease.
Roy A. Pleasants, II, PharmD
Clinical and Investigational Pharmacist
Duke Asthma, Allergy, and Airways Center
Division of Pulmonary, Allergy, and Critical Care Medicine
Duke University School of Medicine
Research Associate in Pulmonary Medicine
Department of Pulmonary Medicine
Durham Veterans Administration Medical Center
CoChair, NC COPD Taskforce
Durham, North Carolina
Roy A. Pleasants, II, PharmD, has a financial interest/relationship or affiliation in the form of:
Consultant for Boehringer Ingelheim and Teva Pharmaceuticals.
Roy A. Pleasants, II, PharmD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Delivery devices being investigated for COPD treatments.
Joseph G. Crocetti, DO
Abington Jefferson Health
Joseph G. Crocetti, DO, has no financial interests/relationships or affiliations in relation to this activity.
Nancy Nesser, JD, PharmD
Oklahoma Health Care Authority
Oklahoma City, OK
Nancy Nesser, JD, PharmD, has no financial interests/relationships or affiliations in relation to this activity.
Kate Nelson, PhD
PVI, PeerView Institute for Medical Education
The information provided at this CME/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Providership, Credit & Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 0.5 contact hours (0.05 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-16-005-H01-P.
This CME/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by educational grants from Sunovion Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.
Copyright © 2000-2016, PeerView Press - Medical Education Resource